Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc (NQ: RPTX )

2.970 +0.130 (+4.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 112,648
Open 2.900
Bid (Size) 2.850 (1)
Ask (Size) 3.400 (5)
Prev. Close 2.840
Today's Range 2.820 - 3.070
52wk Range 2.710 - 8.490
Shares Outstanding 42,088,446
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire

Performance

YTD
-59.26%
-59.26%
1 Month
-15.62%
-15.62%
3 Month
N/A
N/A
6 Month
-4.19%
-4.19%
1 Year
-39.14%
-39.14%

More News

Read More
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
From Repare Therapeutics Inc.
Via Business Wire
Why RingCentral Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
From Debiopharm
Via Business Wire
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
From Repare Therapeutics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.